Status:
RECRUITING
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Lead Sponsor:
Duke University
Conditions:
Oligometastasis
Metastatic Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.
Eligibility Criteria
Inclusion
- Age ≥ 18 years of age
- Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment
- Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s)
- Patient must sign study-specific informed consent
Exclusion
- • None
Key Trial Info
Start Date :
September 26 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2029
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04085029
Start Date
September 26 2019
End Date
September 1 2029
Last Update
February 7 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke Cancer Institute Cary
Cary, North Carolina, United States, 27518
2
Durham Veterans Administration Health Care System (DVAHCS)
Durham, North Carolina, United States, 27705
3
Duke University Medical Center
Durham, North Carolina, United States, 27710
4
Duke Women's Cancer Care Raleigh
Raleigh, North Carolina, United States, 27607